COVID-19 Pandemic Lockdown Effect in Adolescents and Young Adults With Type 1 Diabetes: Positive Results of an Unpreceded Challenge for Telemedicine and Patient Self-management (COVIDIABADO)
Observational Study of Glycemic Control and Self-management of Young People (Aged 13 to 25 Years ) With Type 1 Diabetes During COVID-19 Lockdown.
Lockdown resulting from the COVID-19 pandemic was an unpreceded model of the impact of lifestyle on chronic diseases, especially for adolescents and young adults with type 1 diabetes (T1D) whose lifestyle is known to strongly impact disease management. The investigators aimed to assess changes in self-monitoring and glycemic control in this population before, during, and after the two-month French lockdown. Te investigators hypothesized an improvement in glucose control and glucose sensor usage.
The protocol will include all patients with T1D from 13 to 25 years old using a flash glucose monitoring related to the LibreView cloud platform.
The primary outcome, evolution of percentage of glucose time in range 70-180 mg/dL (TIR), and secondary outcomes (glucose management indicator GMI, time spent below range TBR, and sensor usage) will be analyzed with a linear mixed-effects regression model.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Continuous glucose monitoring (CGM) data will be collected from the cloud-based platform, LibreView.
Data will be collected for patients from Sud-Francilien hospital (Corbeil-Essonnes, France) and Kremlin-Bicêtre hospital (Kremlin-Bicêtre, France). Data related to glucose control and sensor usage will be collected from the Libreview platform. Data related to patients' characteristics, treatment and telemedicine visits (number of contacts with health professionals) will be collected from the medical record and confirmed with telephone-administered questionnaire.
The lockdown imposed by the French government occurred from March 17 to May 10, 2020. Therefore, outcomes will be assessed 4 times: the month before lockdown, during the first month, the second month of lockdown, and one month after lockdown ended.
Potential confounding factors will be studied: age, gender, type of insulin delivery (multiple daily injections, MDI; insulin pump), contacts with health professionals (physician or nurse).
Descriptive statistics will include means with standard deviations, numbers of patients and percentages.
Outcomes will be analysed with a linear mixed-effects regression model. Analyses will be performed with R studio version 3.5.0.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
France
-
Corbeil-Essonnes, France, France, 91100
- Centre Hospitalier Sud Francilien
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
The population will be selected from two university general hospitals of the region of Ile de France (France): Kremlin-Bicetre hospital and Sud-Francilien hospital.
The population will be aged from to 13 to 25 years at the beginning of lockdown.
La description
Inclusion Criteria:
- Type 1 diabetes
- Age between 13 and 25 years
- use of a flash glucose monitoring related to the LibreView cloud platform
- patients follow-up by the diabetes department of Hopital Sud Francilien or the diabetes department of Hôpital Bicêtre.
- patient informed of the study and not having objected to it.
Exclusion Criteria:
- patients out of France during lockdown
- other type of diabetes
- Duration of diabetes of less than one year
- patient aged under 13 years or above 26 years old
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Changes in percentage of time spent in range 70-180 mg/dL after lockdown compared to before lockdown
Délai: Measure repeated 2 times : month before lockdown (28 days), after lockdown
|
Percentage of time spent in glucose range from 70 to 180 mg/dL over a month (28 days) according to continuous glucose monitoring data collected on Libreview.
|
Measure repeated 2 times : month before lockdown (28 days), after lockdown
|
|
Changes in percentage of time spent in range 70-180 mg/dL during first month of lockdown compared to before lockdown
Délai: Measure repeated 2 times : month before lockdown (28 days), first month of lockdown (28 days)
|
Percentage of time spent in glucose range from 70 to 180 mg/dL over a month (28 days) according to continuous glucose monitoring data collected on Libreview.
|
Measure repeated 2 times : month before lockdown (28 days), first month of lockdown (28 days)
|
|
Changes in percentage of time spent in range 70-180 mg/dL during second month of lockdown compared to before lockdown
Délai: Measure repeated 2 times : month before lockdown (28 days), second month of lockdown (28 days)
|
Percentage of time spent in glucose range from 70 to 180 mg/dL over a month (28 days) according to continuous glucose monitoring data collected on Libreview.
|
Measure repeated 2 times : month before lockdown (28 days), second month of lockdown (28 days)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Evolution of glucose management indicator (GMI) compared to before lockdown.
Délai: Measures repeated 4 times (including 28 days of data for each): month before lockdown (28 days), first month of lockdown (28 days), second month of lockdown (28 days), first month after lockdown (28 days).
|
Glucose Management Indicator (GMI) approximates the laboratory A1C level expected based on average glucose measured using continuous glucose monitoring data collected on Libreview.
|
Measures repeated 4 times (including 28 days of data for each): month before lockdown (28 days), first month of lockdown (28 days), second month of lockdown (28 days), first month after lockdown (28 days).
|
|
Evolution of glucose time spent below range <54 mg/dL
Délai: Measure repeated 4 times (including 28 days of data for each): month before lockdown (28 days), first month of lockdown (28 days), second month of lockdown (28 days), first month after lockdown (28 days).
|
Percentage of time spent in this glucose range in a month (28 days) according to continuous glucose monitoring data collected on Libreview.
|
Measure repeated 4 times (including 28 days of data for each): month before lockdown (28 days), first month of lockdown (28 days), second month of lockdown (28 days), first month after lockdown (28 days).
|
|
Evolution of glucose time spent below range 54 - 70 mg/dL
Délai: Measure repeated 4 times (including 28 days of data for each): month before lockdown (28 days), first month of lockdown (28 days), second month of lockdown (28 days), first month after lockdown (28 days).
|
Percentage of time spent in this glucose range in a month (28 days) according to continuous glucose monitoring data collected on Libreview.
|
Measure repeated 4 times (including 28 days of data for each): month before lockdown (28 days), first month of lockdown (28 days), second month of lockdown (28 days), first month after lockdown (28 days).
|
|
Evolution of glucose time spent below range 180-250 mg/dL
Délai: Measure repeated 4 times (including 28 days of data for each): month before lockdown (28 days), first month of lockdown (28 days), second month of lockdown (28 days), first month after lockdown (28 days).
|
Percentage of time spent in this glucose range in a month (28 days) according to continuous glucose monitoring data collected on Libreview.
|
Measure repeated 4 times (including 28 days of data for each): month before lockdown (28 days), first month of lockdown (28 days), second month of lockdown (28 days), first month after lockdown (28 days).
|
|
Evolution of glucose time spent below range > 250 mg/dL
Délai: Measure repeated 4 times (including 28 days of data for each): month before lockdown (28 days), first month of lockdown (28 days), second month of lockdown (28 days), first month after lockdown (28 days).
|
Percentage of time spent in this glucose range in a month (28 days) according to continuous glucose monitoring data collected on Libreview.
|
Measure repeated 4 times (including 28 days of data for each): month before lockdown (28 days), first month of lockdown (28 days), second month of lockdown (28 days), first month after lockdown (28 days).
|
|
Evolution of average glucose in mg/dL compared to before lockdown.
Délai: Measure repeated 4 times (including 28 days of data for each): month before lockdown (28 days), first month of lockdown (28 days), second month of lockdown (28 days), first month after lockdown (28 days).
|
Average glucose level in a month (28 days) according to continuous glucose monitoring data collected on Libreview.
|
Measure repeated 4 times (including 28 days of data for each): month before lockdown (28 days), first month of lockdown (28 days), second month of lockdown (28 days), first month after lockdown (28 days).
|
|
Evolution of hypoglycaemia frequency compared to before lockdown.
Délai: Measure repeated 4 times (including 28 days of data for each): month before lockdown (28 days), first month of lockdown (28 days), second month of lockdown (28 days), first month after lockdown (28 days).
|
Number of hypoglycaemia events (glycemia under 70 mg/dL during at least 15 minutes) in a month (28 days) according to continuous glucose monitoring data collected on Libreview.
|
Measure repeated 4 times (including 28 days of data for each): month before lockdown (28 days), first month of lockdown (28 days), second month of lockdown (28 days), first month after lockdown (28 days).
|
|
Evolution of glucose sensor use compared to before lockdown.
Délai: Measures repeated 4 times (including 28 days of data for each): month before lockdown (28 days), first month of lockdown (28 days), second month of lockdown (28 days), first month after lockdown (28 days).
|
The level of glucose data collected related to the glucose monitoring frequency and the number of scans with continuous glucose monitoring data collected on Libreview.
|
Measures repeated 4 times (including 28 days of data for each): month before lockdown (28 days), first month of lockdown (28 days), second month of lockdown (28 days), first month after lockdown (28 days).
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Alfred PENFORNIS, MD PhD, Centre Hospitalier Sud Francilien
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du système endocrinien
- Maladies métaboliques
- Maladies auto-immunes
- Maladies du système immunitaire
- Infections des voies respiratoires
- Infections
- Infections par virus à ARN
- Maladies virales
- Maladies des voies respiratoires
- Maladies pulmonaires
- Troubles du métabolisme du glucose
- Diabète sucré
- Pneumonie virale
- Pneumonie
- Infections à coronavirus
- Infections à Coronaviridae
- Infections à Nidovirales
- Maladies nutritionnelles et métaboliques
- COVID-19 [feminine]
- Diabète sucré, type 1
Autres numéros d'identification d'étude
- 2020-A02760-39
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .